A cost-effective policy on alcohol abuse, diagnosis and monitoring in clinics, industries and forensic settings will improve clinical outcome, reduce drink driving, decrease accidents in major industries and consequently save the cost spent on alcohol related expenses.
Carbohydrate Deficient Transferrin (CDT) is the most reliable blood marker for chronic alcohol abuse. An average daily consumption of more than 60 g of alcohol during the previous 2 weeks increases the percentage of this marker. Increased CDT levels indicate that alcohol is disrupting the normal chemistry of the liver cells. In most people, an elevated CDT will return to normal during several weeks of alcohol abstinence.
CDT is specific for heavy alcohol use; 30% reduction in CDT is consistent with a substantial reduction in alcohol intake. In many aspects, CDT has characteristics similar to HbA1c and other blood tests that change based on diet and/or therapeutical intervention. An increase in CDT serves as an indication that the person has returned to heavy drinking, providing an efficient and specific monitoring tool for healthcare professionals.
CDT is the marker recommended by IFCC for chronic alcohol abuse.